Bellicum Pharmaceuticals Inc.: Molecular switch technology and co-stim domains enables pharmacologic control over cells for enhanced efficacy and safety. Lead (registrational EU) program: Ph2 for rivo-cel (alpha/beta addback T-cell therapy for post allogeneic HSTC in non-malignant and malignant diseases). Positive late interim analysis on rivo-cel exp at ASH 2018; full dataset (N=234) exp H1 19. BPX-601: GoCAR-T featuring iMC (inducible MyD88/CD40) activation switch targeting PSCA expressing solid tumors; BPX-701: TCR targeting PRAME.
Based in...
US - West South Central
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Oncology, Rare Disease
Public, USA
Market Cap
Therapeutic Modalities
Cell Therapy
2130 West Holcombe Boulevard, Suite 800
Texas Life Science Plaza
Houston, TX 77030
United States

Top 10 Holders of Bellicum Pharmaceuticals Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Baker Bros. Advisors LP 5.02 249,123 1.71 13F 6/30/20
Renaissance Technologies LLC 3.73 185,071 1.27 13F 6/30/20
Vanguard Group, Inc. (Subfiler) 3.51 174,383 1.20 13F 6/30/20
The Vanguard Group, Inc. 3.44 170,831 1.17 Funds 9/30/20
Frazier Management LLC 2.12 105,144 0.72 13F 6/30/20
BlackRock Institutional Trust Co. NA 1.69 83,798 0.58 13F 6/30/20
Principal Financial Group, Inc. 1.07 53,238 0.37 13F 6/30/20
Principal Global Investors LLC 0.97 48,900 0.34 Funds 6/30/20
Geode Capital Management LLC 0.90 44,750 0.31 13F 6/30/20
Bridgeway Capital Management, Inc. 0.59 29,180 0.20 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.